{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T11:46:36Z","timestamp":1769600796690,"version":"3.49.0"},"reference-count":19,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2014,4,1]],"date-time":"2014-04-01T00:00:00Z","timestamp":1396310400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,12]],"date-time":"2019-11-12T00:00:00Z","timestamp":1573516800000},"content-version":"vor","delay-in-days":2051,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"name":"European Commission Framework Programme VI","award":["FP6-LSHC-CT-2004-503426"],"award-info":[{"award-number":["FP6-LSHC-CT-2004-503426"]}]},{"DOI":"10.13039\/100001006","name":"Breast Cancer Research Foundation","doi-asserted-by":"crossref","award":["BCRF 2007-2008"],"award-info":[{"award-number":["BCRF 2007-2008"]}],"id":[{"id":"10.13039\/100001006","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Novartis, F. Hoffman La Roche, Sanofi-Aventis"},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"crossref"}]},{"name":"EBCC-Breast Cancer Working Group"},{"name":"MINDACT biobank"},{"name":"Jacqueline Seroussi Memorial Foundation"},{"name":"Prix Mois du Cancer du Sein","award":["SG05-0922-02"],"award-info":[{"award-number":["SG05-0922-02"]}]},{"name":"Fondation Belge Contre le Cancer","award":["SCIE 2005-27"],"award-info":[{"award-number":["SCIE 2005-27"]}]},{"DOI":"10.13039\/501100004622","name":"Dutch Cancer Society","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Association Le Cancer du Sein, Parlons-en!, Deutsche Krebshilfe"},{"name":"Grant Simpson Trust and Cancer Research UK"},{"DOI":"10.13039\/501100004898","name":"EORTC Charitable Trust","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004898","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Agendia"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2014,4]]},"DOI":"10.1093\/annonc\/mdu026","type":"journal-article","created":{"date-parts":[[2014,3,25]],"date-time":"2014-03-25T10:38:42Z","timestamp":1395743922000},"page":"816-823","source":"Crossref","is-referenced-by-count":49,"title":["High concordance of protein (by IHC), gene (by FISH; HER2 only), and microarray readout (by TargetPrint) of ER, PgR, and HER2: results from the EORTC 10041\/BIG 03-04 MINDACT trial"],"prefix":"10.1016","volume":"25","author":[{"given":"G.","family":"Viale","sequence":"first","affiliation":[]},{"given":"L.","family":"Slaets","sequence":"additional","affiliation":[]},{"given":"J.","family":"Bogaerts","sequence":"additional","affiliation":[]},{"given":"E.","family":"Rutgers","sequence":"additional","affiliation":[]},{"given":"L.","family":"van't Veer","sequence":"additional","affiliation":[]},{"given":"M.J.","family":"Piccart-Gebhart","sequence":"additional","affiliation":[]},{"given":"F.A.","family":"de Snoo","sequence":"additional","affiliation":[]},{"given":"L.","family":"Stork-Sloots","sequence":"additional","affiliation":[]},{"given":"L.","family":"Russo","sequence":"additional","affiliation":[]},{"given":"P.","family":"Dell'Orto","sequence":"additional","affiliation":[]},{"given":"J.","family":"van den Akker","sequence":"additional","affiliation":[]},{"given":"A.","family":"Glas","sequence":"additional","affiliation":[]},{"given":"F.","family":"Cardoso","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdu026_bb0010","doi-asserted-by":"crossref","first-page":"2742","DOI":"10.1016\/j.ejca.2011.09.016","article-title":"The EORTC 10041\/BIG 03-04 MINDACT trial is feasible: results of the pilot phase","volume":"00","author":"Rutgers","year":"2011","journal-title":"Eur J Cancer"},{"key":"10.1093\/annonc\/mdu026_bb0015","doi-asserted-by":"crossref","first-page":"2784","DOI":"10.1200\/JCO.2009.25.6529","article-title":"American Society of Clinical Oncology\/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer","volume":"28","author":"Hammond","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdu026_bb0020","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1093\/annonc\/mdr304","article-title":"Strategies for subtypes\u2014dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011","volume":"22","author":"Goldhirsch","year":"2011","journal-title":"Ann Oncol"},{"issue":"Suppl 6","key":"10.1093\/annonc\/mdu026_bb0025","doi-asserted-by":"crossref","first-page":"vi12","DOI":"10.1093\/annonc\/mdr371","article-title":"Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"22","author":"Aebi","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdu026_bb0030","unstructured":"National Comprehensive Cancer Network: NCCN Clinical Practice Guidelines in Oncology. Breast Cancer. Version 2.2013. 2013. http:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/breast.pdf (23 December 2013, date last accessed)"},{"key":"10.1093\/annonc\/mdu026_bb0035","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1200\/JCO.2007.15.6638","article-title":"Inconsistent criteria used in American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer","volume":"26","author":"Cardoso","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdu026_bb0040","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1038\/ncponc0591","article-title":"Gene signature evaluation as a prognostic tool: challenges in the design of the MINDACT trial","volume":"3","author":"Bogaerts","year":"2006","journal-title":"Nat Clin Pract Oncol"},{"key":"10.1093\/annonc\/mdu026_bb0045","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1136\/jcp.53.2.125","article-title":"Reliability of immunohistochemical demonstration of oestrogen receptors in routine practice: interlaboratory variance in the sensitivity of detection and evaluation of scoring systems","volume":"53","author":"Rhodes","year":"2000","journal-title":"J Clin Pathol"},{"key":"10.1093\/annonc\/mdu026_bb0050","doi-asserted-by":"crossref","first-page":"7003","DOI":"10.1158\/1078-0432.CCR-09-0449","article-title":"Microarray-based determination of estrogen receptor, progesterone receptor, and HER2 receptor status in breast cancer","volume":"15","author":"Roepman","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdu026_bb0055","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1186\/1471-2164-7-278","article-title":"Converting a breast cancer microarray signature into a high-throughput diagnostic test","volume":"7","author":"Glas","year":"2006","journal-title":"BMC Genomics"},{"key":"10.1093\/annonc\/mdu026_bb0060","unstructured":"US Food and Drug Administration: Guidance for industry and FDA staff: Statistical guidance on reporting results from studies evaluating diagnostic tests. http:\/\/medical.cms.itri.org.tw\/pdf\/u14.pdf (23 December 2013, date last accessed)"},{"key":"10.1093\/annonc\/mdu026_bb0065","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1177\/001316446002000104","article-title":"A coefficient of agreement for nominal scales","volume":"20","author":"Cohen","year":"1960","journal-title":"Educ Psychol Meas"},{"key":"10.1093\/annonc\/mdu026_bb0070","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1200\/JCO.2007.14.3222","article-title":"Clinical application of the 70-gene profile: the MINDACT trial","volume":"26","author":"Cardoso","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdu026_bb0075","doi-asserted-by":"crossref","first-page":"e36559","DOI":"10.1371\/journal.pone.0036559","article-title":"Quantitative in situ measurement of estrogen receptor mRNA predicts response to tamoxifen","volume":"7","author":"Bordeaux","year":"2012","journal-title":"PLoS One"},{"key":"10.1093\/annonc\/mdu026_bb0080","doi-asserted-by":"crossref","first-page":"5222","DOI":"10.1158\/1078-0432.CCR-10-1282","article-title":"A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer","volume":"16","author":"Nielsen","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdu026_bb0085","doi-asserted-by":"crossref","first-page":"4611","DOI":"10.1200\/JCO.2006.06.6944","article-title":"The HOXB13:IL17BR expression index is a prognostic factor in early-stage breast cancer","volume":"24","author":"Ma","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdu026_bb0090","doi-asserted-by":"crossref","first-page":"4300","DOI":"10.1200\/JCO.2009.24.8211","article-title":"Human epidermal growth factor receptor 2 assessment in a case-control study: comparison of fluorescence in situ hybridization and quantitative reverse transcription polymerase chain reaction performed by central laboratories","volume":"28","author":"Baehner","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdu026_bb0095","doi-asserted-by":"crossref","first-page":"4279","DOI":"10.1200\/JCO.2011.34.7963","article-title":"High false-negative rate of HER2 quantitative reverse transcription polymerase chain reaction of the Oncotype DX test: an independent quality assurance study","volume":"29","author":"Dabbs","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdu026_bb0100","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1093\/annonc\/mdm059","article-title":"Quantitative real-time PCR analysis and microarray-based RNA expression of HER2 in relation to outcome","volume":"18","author":"Bergqvist","year":"2007","journal-title":"Ann Oncol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419365081?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419365081?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/25\/4\/816\/16703376\/mdu026.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T20:06:20Z","timestamp":1625169980000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419365081"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4]]},"references-count":19,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,4]]}},"alternative-id":["S0923753419365081"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdu026","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2014,4]]}}}